Compare EZGO & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZGO | EOCN |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.9M |
| IPO Year | 2020 | 2013 |
| Metric | EZGO | EOCN |
|---|---|---|
| Price | $1.78 | $1.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 80.9K | 8.9K |
| Earning Date | 12-29-2026 | 12-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $1.79 |
| 52 Week High | $3.30 | $3.80 |
| Indicator | EZGO | EOCN |
|---|---|---|
| Relative Strength Index (RSI) | 70.93 | 22.75 |
| Support Level | $0.83 | N/A |
| Resistance Level | $2.46 | $2.98 |
| Average True Range (ATR) | 0.25 | 0.30 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 75.49 | 1.64 |
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.